Health ❯ Healthcare ❯ Medical Research ❯ Clinical Trials

Alzheimer's Disease

Biogen's Tau Drug Cuts Brain Tau but Misses Dose‑Response Goal

Data suggesting that lowering tau can slow Alzheimer’s progression have prompted Biogen to plan a pivotal Phase 3 in 2027.

Major Review Says New Alzheimer’s Antibodies Offer No Meaningful Benefit

WHO Endorses Long-Term GLP-1 Use for Obesity as Indian Ruling Opens Production and Safety Alerts Expand

Novo Nordisk’s Oral Semaglutide Fails to Slow Alzheimer’s in Dual Phase 3 Trials

UK Launches NHS Trial of £100 Blood Test to Speed Alzheimer’s Diagnosis

AI Stratification Uncovers Alzheimer’s Drug Efficacy, Drives NHS Toward Precision Trials

UNM Launches Phase 1a/1b Trial of Tau-Targeting Alzheimer’s Vaccine